PREGNANCY & CHILDHOOD

The Role of HMOs in Reducing NEC

The Promising Role of HMOs in Reducing Risk of NEC

Sub Heading

New research suggests that human milk oligosaccharides may play a pivotal role in reducing necrotizing enterocolitis

Main Image

Alt text

Duration
JUL. 22, 2020  4 MIN. READ
Description

Welcoming a new baby into the world should be an exciting time if you're an expecting parent. But when your child is born premature, it's normal to worry about the possible health challenges and complications they may face.

Necrotizing enterocolitis, also known as NEC, is a rare condition that premature babies may develop during their first weeks of life. Though NEC can be managed, its effect on a child's health can be serious. NEC prevention may also be possible, according to new preliminary studies. 

Emerging preclinical research from Johns Hopkins and Abbott suggests that when premature babies are fed breast milk, the presence of human milk oligosaccharides (HMOs) in the milk may help reduce their chances of developing NEC. We sat down with Rachael Buck, Ph.D., a research fellow at Abbott Nutrition, to discuss necrotizing enterocolitis and the promising research surrounding it.

What Is Necrotizing Enterocolitis?

NEC is a disease that can affect newborns by causing inflammation in their intestines. With NEC, bacteria inside the intestinal tract can leak into the intestinal wall. Babies with NEC require a period of gut rest, which means they are temporarily nourished by intravenous nutrition.  NEC may be fatal, depending upon how severely NEC affects the newborn, Buck explains.

The specific cause of NEC is unknown, but it's most often seen in very low birth weight premature babies. In the United States, about 10% of babies who are born prematurely develop NEC. "While there are available NEC treatments, preventive strategies to aid infants at high risk for the disease are needed," says Buck.

One prevention strategy that's already showing promise involves the use of HMOs. In new preclinical research from Johns Hopkins and Abbott, HMOs were shown to effectively prevent instances of necrotizing enterocolitis in animal models.

What Are Human Milk Oligosaccharides?

Behind fat and lactose (carbohydrate), HMOs are the third most abundant component in breast milk. These are special prebiotics that feed beneficial bacteria and play a positive role in the development of the infant immune system. HMOs cannot be broken down or digested by your child, but they are digested by the beneficial bacteria that reside in their gut.

There are around 200 different HMOs in breast milk, but the most abundant  one is 2'-FL HMO. A structurally identical version of the 2'-FL HMO that's present in breast milk can be found in certain Similac® formulas.

"For parents who cannot or choose not to breastfeed, or those who need to supplement, using an infant formula with HMO 2'-fucosyllactose (2'-FL HMO) can help to support a baby's developing immune system similar to breastfed infants," says Buck.

When breastfeeding isn't an option, some mothers opt to pump breast milk for their preterm babies, which is often given to them through a feeding tube. This allows them to still receive the immune benefits of HMOs from their mother.

How Do HMOs Help With NEC Prevention?

“We now know, for the first time, how HMOs protect against NEC — through toll-like receptor 4 inhibition, this is a critical development that sets the stage for us to conduct additional research and testing with the goal of developing feeding interventions that incorporate these potentially lifesaving ingredients to combat this disease.”

Rachael Buck, PhD, Director of pre-clinical research at Abbott

On a cellular level, NEC may be caused by the enhanced expression of certain proteins involved in inflammation, called toll-like receptor 4 (TLR4) in the intestines of  premature infants. New research suggests that two HMOs — 2'-FL and 6'-SL — bind to TLR4 and dramatically curb intestinal inflammation. Other research suggests that premature infants who aren't breastfed have a 2.4 times greater risk of developing necrotizing enterocolitis.

"We now know, for the first time, how HMOs protect against NEC — through toll-like receptor 4 inhibition," explains Buck. "This is a critical development that sets the stage for us to conduct additional research and testing with the goal of developing feeding interventions that incorporate these potentially lifesaving ingredients to combat this disease."

"Future HMO research looks very promising and Abbott is committed to advancing this rich area of science-based nutrition," says Buck.

What Does the Future of Preemie Nutrition Look Like?

"HMOs are potentially lifesaving ingredients with respect to near-term and longer-term health outcomes in this vulnerable population," explains Buck. Although HMOs are not currently available in Similac's premature infant formulas, this is an active area of research for Buck's team. "We are committed to optimizing these formulas based on clinical research in preterm infants," she adds.

If your baby is born prematurely, understanding that mother’s own breastmilk is best for your baby is key to delivering not only nutrients, but also HMOs and other immune-protective factors.  And since breastmilk protects against NEC, work closely with your baby’s physician and dietitian to understand how to support a good breastmilk supply, so that your preterm baby gets as much breastmilk as possible.  

he Power of Human Milk Oligosaccharides in Infant Nutrition

Main Image

A mother holds a sleeping baby in her arms.

Heading

The Power of Human Milk Oligosaccharides

Description

Breast milk is the gold standard for babies’ nutrition — with a perfect blend of proteins, fats, carbohydrates, vitamins, minerals and other components that support a baby's immune system. Within this nutritional powerhouse, there are unique prebiotics called human milk oligosaccharides (HMOs). Based on over two decades of research, experts believe HMOs could be one of the factors behind breast milk's immune system-supporting properties.

Until 2016, HMOs were only found in human breast milk and not available to exclusively formula-fed babies. Now, thanks to cutting-edge research, those who choose to use formula can opt to feed their babies formula that has a blend of five different HMOs.  

Reference Page Path
/content/an/newsroom/us/en/pregnancy-childhood/prenatal-breastfeeding/the-power-of-human-milk-oligosaccharides.html

The Promising Role of HMOs in Reducing Risk of NEC

Main Image

Alt text

Description

Welcoming a new baby into the world should be an exciting time if you're an expecting parent. But when your child is born premature, it's normal to worry about the possible health challenges and complications they may face.

Necrotizing enterocolitis, also known as NEC, is a rare condition that premature babies may develop during their first weeks of life. Though NEC can be managed, its effect on a child's health can be serious. NEC prevention may also be possible, according to new preliminary studies. 

Reference Page Path
/content/an/newsroom/us/en/pregnancy-childhood/prenatal-breastfeeding/the-promising-role-of-hmos-in-reducing-risk-of-nec.html

SELF QUIZ

 
Required

RELATED PRODUCT

SIMILAC PRO-TOTAL COMFORT

Parents reported a significant reduction in fussiness, gassiness, and crying after one day.

NUTRITION IS THE FOUNDATION FOR LIVING YOUR BEST LIFE. THAT’S WHY WE WORK HARD TO ADVANCE AND SHARE THE LATEST SCIENCE AND CREATE BETTER WAYS TO NOURISH YOUR BODY AT EVERY STAGE OF LIFE.

Subscribe Policy

I understand and agree that the information I’ve provided will be used according to the terms of Abbott’s Privacy PolicyTerms and conditions apply.

Unless otherwise specified, all product and services names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, tradename, or trade dress in the site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy.

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

Collapse
Learn more about cookies